Audentes Therapeutics, Inc. Balance Sheet

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Balance Sheets

In millions of USD, except per-share amounts

	Q3 FY2019 As of Sep 30, 2019	Q2 FY2019 As of Jun 30, 2019	Q1 FY2019 As of Mar 31, 2019	Q4 FY2018 As of Dec 31, 2018	Q3 FY2018 As of Sep 30, 2018	Q2 FY2018 As of Jun 30, 2018	Q1 FY2018 As of Mar 31, 2018	Q4 FY2017 As of Dec 31, 2017	Q3 FY2017 As of Sep 30, 2017	Q2 FY2017 As of Jun 30, 2017	Q1 FY2017 As of Mar 31, 2017	Q4 FY2016 As of Dec 31, 2016	Q3 FY2016 As of Sep 30, 2016	Q2 FY2016 As of Jun 30, 2016
Assets
Current assets:
Cash and cash equivalents
Short-term investments
Restricted cash
Prepaid expenses and other current assets
Total current assets
Restricted cash - long-term
Long-term investments
Property and equipment, net
Right-of-use assets
Goodwill
Intangible assets
Other assets
Total assets
Liabilities and Stockholders' Equity
Current liabilities:
Accounts payable
Accrued liabilities
Facility lease obligations
Operating lease liabilities
Contingent acquisition consideration payable
Deferred rent
Total current liabilities
Facility lease obligations
Deferred rent and asset retirement obligation - long-term
Other long-term liabilities
Deferred rent - long-term
Asset retirement obligation - long-term
Operating lease liabilities - long-term
Contingent acquisition consideration payable - long-term
Deferred tax liability, net
Total liabilities
Stockholders' equity:
Preferred stock, $0.00001 par value, 10,000,000 shares authorized as of September 30, 2019 (unaudited) and December 31, 2018; 0 shares issued and outstanding as of September 30, 2019 (unaudited) and December 31, 2018, respectively
Convertible Preferred Stock, Series Seed
Convertible Preferred Stock, Series A
Convertible Preferred Stock, Series B
Convertible Preferred Stock, Series C
Total preferred stock, $0.00001 par value, 10,000,000 shares authorized as of September 30, 2019 (unaudited) and December 31, 2018; 0 shares issued and outstanding as of September 30, 2019 (unaudited) and December 31, 2018, respectively

Common stock, $0.00001 par value, 300,000,000 shares authorized as of September 30, 2019 (unaudited) and December 31, 2018; 45,740,575 and 43,546,786 shares issued and outstanding as of September 30, 2019 (unaudited) and December 31, 2018, respectively
Additional paid-in capital
Accumulated deficit
Accumulated other comprehensive income (loss)
Total stockholders' equity
Total liabilities and stockholders' equity

Comments